Parkinson disease (PD) is a chronic, progressive neurological disease that is associated
with a loss of dopaminergic neurons in the substantia nigra pars compacta of the brain. The …

Antagonism of protein–protein interactions (PPIs) with small molecules is becoming more
feasible as a therapeutic approach. Successful PPI inhibitors tend to target proteins …

Parkinson's disease (PD) is defined as a complex disorder with multifactorial pathogenesis,
yet a more accurate definition could be that PD is not a single entity, but rather a mixture of …

Toll-like receptor (TLR) signaling is initiated by dimerization of intracellular Toll/IL-1 receptor
resistance (TIR) domains. For all TLRs except TLR3, recruitment of the adapter, myeloid …

Abstract Background The R1441G mutation in the leucine-rich repeat kinase 2 (LRRK2)
gene results in late-onset Parkinson's disease (PD). Peripheral inflammation and gut …

Current therapeutic approaches for Parkinson's disease (PD) are based around treatments
that alleviate symptoms but do not slow or prevent disease progression. As such, alternative …

Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting millions of
people worldwide. Mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) are …

Parkinson's Disease (PD) affects millions of people worldwide with no cure to halt the
progress of the disease. Leucine-rich repeat kinase 2 (LRRK2) is the most common genetic …

Mutations in the gene coding for leucine-rich repeat kinase 2 (LRRK2) are a leading cause
of the inherited form of Parkinson's disease (PD), while LRRK2 overactivation is also …

Mutations in leucine-rich repeat kinase 2 (LRRK2) comprise the most common cause of
familial Parkinson's disease (PD), and sequence variants modify risk for sporadic PD …